This JAMA Forum discusses some key considerations for addressing the question of whether and when prevention interventions are worth the cost.

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity since the US Food & Drug Administration first approved semaglutide (brand name Ozempic/Wegovy) for weight loss in 2021.

th obesity care from 2010 to 2021 in the United States. Research Design: This multiyear cross-sectional study was conducted using Medical Expenditure Panel Survey (MEPS) data, covering respondents ...